Don't even really know where to begin but the level of incompetence at RVX senior management/BoD proves to be astonishing month after month, year after year. Catching up with a bunch of posts, golf's second to last post certainly hi lighted what has been said and consequently miserably failed upon. The attached article to the last post certainly outlines many avenues of potential COVID opportunity which may be minimally or non-dilutive.  You wonder if management is aware of and pursuing any of these avenues.

Aside from the BetonMace2 and the Covid trial I don't know why they aren't coming out of hiding and moving quickly on and talking up the PAH trial.  The posting on clinicaltrial.gov makes it look pretty straightforward and manageable (projected start date in Oct with RVX supplying drug), the market is about 7B/yr growing to almost 11+B/yr by 2030 (Grandview, Polaris), it is a rare disease and there is gov't funding available and the kicker is current drugs are quite expensive with average monthly costs being $2200-$9300 (Caremark) and Mercks new entry into this space, Sotatercept (approved last month), coming in at a whopping projected $20,000/mo. The fact that Merck would enter this market with a drug this expensive and the fact that the folks at Laval are ready to go suggests to me there must be potential opportunity for RVX here. Why aren't they talking about this, to me it would at least give this company some relevance.

To me funding BetonMace2 from a Zenith generated royalty is not a bad idea but surely other business can be accomplished in the interim. However IMO the idea of current management/BoD running a biotech investment company is both laughable and sickening, I would imagine you would have to work pretty hard to assemble a collection of business "professionals" who have accomplished so little for so long.